Brief: Basilea Initiates Phase 3 Study With Antifungal Fosmanogepix In Invasive Mold Infections

Basilea Pharmaceutica AG, Allschwil

29/07/2025 06:17

July 29 (Reuters) - BASILEA PHARMACEUTICA AG ALLSCHWIL BSLN.S:

INITIATES PHASE 3 STUDY WITH ANTIFUNGAL FOSMANOGEPIX IN INVASIVE MOLD INFECTIONS

STUDY COMPLETION EXPECTED IN Q1 2028

Source text: ID:nGNX4g8mdz

Further company coverage: BSLN.S

 (Gdansk Newsroom)

 ((((gdansk.newsroom@thomsonreuters.com ; +48 587785269; ));))